Biomedical subjects

S J Tregear

Publications and source records attributed to S J Tregear.

8 recordsLinked to original sources

PubMed2000

Time course of early mesopic adaptation to luminance decrements and recovery of spatial resolution.

The time course of recovery of spatial resolution following adaptation to a uniform field was measured for test probes presented at lower illuminance than the adapting field. Six observers were tested in a Maxwellian-view system using 20 degrees adapting fields of 1.6-2.6 log photopic trolands. Test stimuli were 7 degrees, 250 ms Gabor patches (1 and 6 cpd) of mean retinal illuminance 2-3 log units lower than the adapting field. During the 9 s after adapting field offset, contrast thresholds for orientation discrimination followed an exponential-decay function and showed longer recovery times for larger illuminance decrements and higher spatial frequency.

Adult↗

PubMed1999

Senescent changes in scotopic contrast sensitivity.

Scotopic contrast sensitivity functions (CSFs) were measured for 50 observers between the ages of 20 and 88 years. Using a maximum-likelihood, 2-alternative, temporal forced-choice threshold-estimation algorithm, scotopic CSFs were measured at 7 spatial frequencies ranging from 0.2 to 3.0 cpd, with mean retinal illuminance equated for observers at -0.85 log scotopic Trolands. For each stimulus condition, eight cycles of a horizontal sinusoidal grating were presented within +/- 1 S.D. of a 2-D Gaussian-spatial envelope and within a 1-s Gaussian-temporal envelope. Stimuli were centered on the nasal retina along the horizontal meridian 6 degrees from the fovea. Scotopic CSFs were found to be low-pass. Statistically significant age-related declines in contrast sensitivities were found for spatial frequencies at or below 1.2 cpd. There was also a statistically significant decrease in the high frequency cut-off with age (P < 0.01). An explanation of these results in terms of optical factors is rejected, while the results are consistent with age-related changes in the magnocellular pathway.

Adult↗

PubMed1998

Screening for ophthalmic disease in older subjects using visual acuity and contrast sensitivity.

OBJECTIVE: Despite early interest in contrast sensitivity as a screening test for ophthalmic disease, most published opinion suggests that there is no benefit over conventional measurement of visual acuity. Taking a primary care perspective of screening, the authors evaluated the ability to discriminate those with any diagnosed ophthalmic disease in a large sample representative of the general population. DESIGN: Retrospective analysis of a clinical, cross-sectional survey. Snellen visual acuity, contrast sensitivity (Arden plates, American Optical contrast sensitivity test), and ophthalmic diagnosis were reported previously. PARTICIPANTS: A sample of 3283 subjects, all aged at least 50 years, were selected randomly from residents of a health district in Sydney, Australia. Ophthalmologic diagnosis (ophthalmic disease presence/absence) had been confirmed for 2522 of these subjects. MAIN OUTCOME MEASURES: Signal detection techniques (the receiver-operating characteristics function [ROC], quality ROC [QROC], and weighted kappa coefficient of association [kappa(r)]) were used to evaluate test discriminability. RESULTS: Because analyses of right and left eyes were almost identical, only right eye results are presented. Advantages of kappa(r) over ROC were shown. Discrimination of those with diagnosed ophthalmic disease from those without ophthalmic disease was best with Arden plate 7 (kappa0.5 = 0.93) and was better than distance Snellen visual acuity (kappa0.5 = 0.59). Arden plate 7 (6.4 cyc/deg) correctly assigned 96% of subjects at its optimal pass-fail criterion. CONCLUSIONS: In the primary care setting, a person older than 50 years of age with reduced contrast sensitivity, as determined by Arden plate 7, requires extra care in subsequent examinations because this person is likely to have an ophthalmic disease.

Aged↗

PubMed1997

Chromatic-contrast threshold impairment in diabetes.

A prospective study was carried out to investigate acquired colour-vision deficits in diabetics using an automated, computer-controlled, cathode-ray-tube based test of chromatic contrast. Chromatic-contrast thresholds estimates were measured along both a red/ green (constant S-cone) confusion axis and a tritan (constant M/L-cone) confusion axis for 305 eyes of 305 diabetics. The diabetic data were partitioned into groups based on a clinical categorisation of retinopathy. The diabetic data were compared with both age-matched and 'lens-equated' control data obtained from a bank of 347 normal subjects. Further analysis of differences between diabetic-status groups was performed. Associations between chromatic contrast threshold estimates and age, duration of disease, and severity of both macular oedema and ischaemia were investigated. The diabetic group was found to have significantly reduced chromatic-contrast threshold estimates when compared with normal controls, even in the absence of retinopathy. This reduction in chromatic contrast was predominantly tritanopic in nature. Interestingly, no reduction in red/green chromatic-contrast threshold estimate was found in diabetics without retinopathy. The tritan deficit seen in diabetics without retinopathy was strongly correlated with duration of disease, but when adjustments were made to account for the effects of duration-dependent lens yellowing, the tritan deficit was no longer apparent. A correlation between both the severity of macular oedema and severity of ischaemia with chromatic-contrast loss was established. Acquired reductions in both red/green and tritan chromatic-contrast threshold estimates seen in diabetics are strongly correlated with the severity of retinopathy. The results provide evidence that the specific tritan deficits seen in diabetics can be explained by the effects of lens yellowing rather than by selective damage of the blue cone system as has been hypothesised by other groups. The results provide support for the potential use of automated CRT-based tests of colour vision in diabetic retinopathy screening protocols.

Adolescent↗

PubMed1996

Colour vision in diabetic and normal pseudophakes is worse than expected.

Automated colour vision testing in pseudophakes showed unexpected results. Chromatic discrimination sensitivity was measured in 22 diabetic pseudophakes with no retinopathy, 23 diabetic pseudophakes with background retinopathy and 34 non-diabetic pseudophakes. These results were compared with those in age-matched normal and diabetic phakic subjects, all of whom had good vision. The diabetics were also matched for retinopathy grading and duration of diabetes. In all three groups, red-green discrimination sensitivity was worse in the pseudophakes when compared with the corresponding phakic subjects (normals, p < 0.001; no retinopathy, p = 0.467; background retinopathy, p = 0.057). However, tritan vision was marginally worse in the normal pseudophake group but was better in the two diabetic pseudophake groups, when compared with phakic controls. This may be due to a reduction in tritan sensitivity in age-matched phakic controls from the effects of increased lens yellowing with age.

Aged↗

PubMed1995

Automated achromatic contrast and chromatic discrimination sensitivity testing in dysthyroid optic neuropathy.

Our experience of patients with dysthyroid eye disease shows that normal chromatic discrimination sensitivity precludes the diagnosis of optic nerve compression (31 patients), and that clinically confirmed optic nerve compression is invariably associated with decreased chromatic discrimination sensitivity thresholds (8 patients). Dysthyroid patients enrolled in this study underwent automated achromatic contrast and chromatic discrimination sensitivity testing on presentation, with repeat assessment of those patients suspected of developing optic nerve compression. If chromatic discrimination sensitivity was decreased, patients were followed up more frequently. If abnormal chromatic discrimination sensitivity was accompanied by a relative afferent pupillary defect (RAPD) or decreased Snellen visual activity (VA), then optic nerve decompression was performed. The automated chromatic discrimination sensitivity test described represents a quick, reproducible and cheap clinical test which we feel is of value in assessing patients with dysthyroid eye disease. We suggest that sequential chromatic discrimination sensitivity assessment is a sensitive and effective way of monitoring patients at risk of dysthyroid optic neuropathy.

Adult↗

PubMed1994

Automated tritan discrimination sensitivity: a new clinical technique for the effective screening of severe diabetic retinopathy.

We have developed and extensively assessed an automated chromatic discrimination test which can be used to screen effectively a diabetic population for sight threatening diabetic eye disease. Equiluminant, sinusoidal, low spatial frequency, chromatic gratings are produced along a tritan confusion axis under computer software control on a high resolution CRT. The correct position of the tritan axis in colour space was calibrated using subjects whilst they were transiently tritanopic. The minimum amplitude about a neutral "grey point" along the tritan confusion axis at which a subject can just distinguish a grating is found using a double staircase reversal algorithm. This measure is taken as the Tritan Discrimination Sensitivity and it is this that we use to flag those diabetics with severe diabetic retinopathy. This computerised tritan discrimination test is quick, non-invasive, easy to operate, inexpensive and reliable. The test-retest reliability coefficient (rho) is 0.92. The tritan discrimination test effectively identifies those diabetics who have or are most at risk of developing severe diabetic retinopathy. The sensitivity of the test for the detection of maculopathy, ischaemic retinopathy (pre-proliferative), and proliferative retinopathy is 97%, 65%, and 93%, respectively. The corrected specificity of the test is 83%. We conclude that the tritan discrimination test has potential for use as a valuable screening tool for the early detection and treatment of severe diabetic retinopathy.

Adolescent↗

PubMed1993

Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.

2'-Deoxy-2'-isocyano-1-beta-D-arabinofuranosylcytosine (8, NCDAC) has been synthesized as a potential antitumor antimetabolite from a corresponding 2'-azido-2'-deoxy-1-beta-D-arabinofuranosyluracil derivative 2a. Uracil and thymine analogues 6a and 6b of 8 were also prepared. Attempts to synthesize 2'-deoxy-2'-isocyanocytidine (14b) failed due to the insertion of the 2'-alpha isocyano group into the 3'-OH group, affording the 2',3'-oxazoline derivative 15b. Stability of the isocyano derivative 6a and 2',3'-oxazoline derivative 15a under basic and acidic conditions were examined. The isocyano group in 6a was stable in basic conditions but unstable even in weakly acidic conditions to furnish the corresponding 2'-beta formamide derivative 17. Compound 15a was easily hydrolyzed the corresponding 2'-alpha formamide derivative 16 on treatment with H2O at room temperature. The cytotoxicity of 8, 6a, and 6b was examined in mouse and human tumor cells in vitro and compared with that of ara-C. Of these nucleosides, 8 was moderately cytotoxic to these cell lines. In vivo antitumor activity of 8 against Lewis lung carcinoma cells was also investigated and 8 showed only moderate tumor volume inhibition.

Animals↗